eligibility_summary
Eligibility: 6 mo–18 y, consented, R/R CD19+ B‑ALL or B‑NHL with measurable dz, post‑HSCT relapse OK, ≥30 d since prior CD19 CAR‑T, life expectancy ≥12 w, ECOG 0–1, adequate counts/organ function, LVEF ≥45%, washouts: steroids, immunosuppressants, antiproliferatives, CNS meds. Exclude: CNS disease (except CNS leukemia), recent non‑conditioning chemo/other trials, active HBV/HCV/HIV, uncontrolled infection, recent MI/unstable angina, neuroautoimmune disease, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Meta10-19, a metabolically armed CD19 CAR-T therapy (autologous, gene‑modified T cells) given after lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog). Mechanism: The CAR targets CD19 on B cells, activating T-cell cytotoxicity and proliferation to eliminate malignant B cells, the “metabolic armoring” is intended to improve T-cell metabolic fitness and persistence in nutrient-poor, immunosuppressive tumor microenvironments. Targets: CD19-positive malignant B cells (B-ALL, B-NHL), key pathways include CD19/CAR signaling (TCR/CD3ζ with costimulation), T-cell cytotoxic effector functions, and resistance to metabolic stress, lymphodepletion reduces host lymphocytes and cytokine sinks to support CAR-T expansion.